ArticlePLoS neglected tropical diseases2016
Intradermal Immunization of Leishmania donovani Centrin Knock-Out Parasites in Combination with Salivary Protein LJM19 from Sand Fly Vector Induces a Durable Protective Immune Response in Hamsters.
Article in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 54 citations in OpenAlex.
- Human sand fly challenge elicits saliva-specific innate and type 1-polarized immunity that promotes Leishmania killing.Communications biology · 2026Article
- Predicting Antileishmanial Activity of Plant-Derived Compounds Using Random Forest Modeling.microPublication biology · 2026Article
- Human sand fly challenge elicits saliva-specific innate and TbioRxiv : the preprint server for biology · 2025Article
- Manufacturing and preclinical toxicity of GLP grade gene deleted attenuated Leishmania donovani parasite vaccine.Scientific reports · 2024Article
- Deletion of MIF gene from live attenuated LdCenScientific reports · 2023Article
- Next-Generation Leishmanization: Revisiting Molecular Targets for Selecting Genetically Engineered Live-AttenuatedMicroorganisms · 2023Review
- Toll-like Receptor-9 (TLR-9) Signaling Is Crucial for Inducing Protective Immunity following Immunization with Genetically Modified Live AttenuatedPathogens (Basel, Switzerland) · 2023Article
- An overview of the sand fly salivary proteins in vaccine development against leishmaniases.Iranian journal of microbiology · 2022Review
- Nanoformulations withVaccines · 2022Article
- Neutrophil-dendritic cell interaction plays an important role in live attenuated Leishmania vaccine induced immunity.PLoS neglected tropical diseases · 2022Article
- Some Good and Some Bad: Sand Fly Salivary Proteins in the Control of Leishmaniasis and in Autoimmunity.Frontiers in cellular and infection microbiology · 2022Review
- Preclinical Assessment of the Immunogenicity of Experimental Leishmania Vaccines.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Vaccines against leishmaniasis: using controlled human infection models to accelerate development.Expert review of vaccines · 2021Article
- Article
- Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasis.Communications biology · 2021Article
- Inoculation of theMicroorganisms · 2021Article
- Essential Role of Neutrophils in the Protective Immune Response Induced by a Live AttenuatedJournal of immunology (Baltimore, Md. : 1950) · 2020Article
- A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing.Nature communications · 2020Article
- Sirolimus enhances the protection achieved by a DNA vaccine against Leishmania infantum.Parasites & vectors · 2020Article
- A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice againstNPJ vaccines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundVisceral leishmaniasis (VL) is a neglected tropical disease and is fatal if untreated. There is no vaccine available against leishmaniasis. The majority of patients with cutaneous leishmaniasis (CL) or VL develop a long-term protective immunity after cure from infection, which indicates that development of an effective vaccine against leishmaniasis is possible. Such protection may also be achieved by immunization with live attenuated parasites that do not cause disease. We have previously reported a protective response in mice, hamsters and dogs with Leishmania donovani centrin gene knock-out parasites (LdCen-/-), a live attenuated parasite with a cell division specific centrin1 gene deletion. In this study we have explored the effects of salivary protein LJM19 as an adjuvant and intradermal (ID) route of immunization on the efficacy of LdCen-/- parasites as a vaccine against virulent L. donovani. METHODOLOGY/PRINCIPAL
findingsTo explore the potential of a combination of LdCen-/- parasites and salivary protein LJM19 as vaccine antigens, LdCen-/- ID immunization followed by ID challenge with virulent L. donovani were performed in hamsters in a 9-month follow up study. We determined parasite burden (serial dilution), antibody production (ELISA) and cytokine expression (qPCR) in these animals. Compared to controls, animals immunized with LdCen-/- + LJM19 induced a strong antibody response, a reduction in spleen and liver parasite burden and a higher expression of pro-inflammatory cytokines after immunization and one month post-challenge. Additionally, a low parasite load in lymph nodes, spleen and liver, and a non-inflamed spleen was observed in immunized animals 9 months after the challenge infection.
conclusionsOur results demonstrate that an ID vaccination using LdCen-/-parasites in combination with sand fly salivary protein LJM19 has the capability to confer long lasting protection against visceral leishmaniasis that is comparable to intravenous or intracardial immunization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.